iRadimed (NASDAQ:IRMD) CEO Sells $226,500.00 in Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 2,500 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $90.60, for a total value of $226,500.00. Following the sale, the chief executive officer directly owned 2,162,500 shares of the company’s stock, valued at approximately $195,922,500. This trade represents a 0.12% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

iRadimed Stock Performance

NASDAQ:IRMD opened at $93.43 on Friday. The firm has a market cap of $1.19 billion, a PE ratio of 51.05 and a beta of 0.91. iRadimed Corporation has a fifty-two week low of $55.11 and a fifty-two week high of $107.90. The business has a 50 day moving average price of $91.20 and a 200-day moving average price of $95.60.

iRadimed (NASDAQ:IRMD) last announced its earnings results on Friday, May 1st. The medical equipment provider reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.03. The company had revenue of $21.98 million during the quarter, compared to the consensus estimate of $21.32 million. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. Research analysts predict that iRadimed Corporation will post 1.52 EPS for the current year.

iRadimed Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, May 29th. Investors of record on Friday, May 15th were issued a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date was Friday, May 15th. iRadimed’s dividend payout ratio is currently 43.72%.

Hedge Funds Weigh In On iRadimed

A number of institutional investors have recently added to or reduced their stakes in the company. CWM LLC increased its holdings in shares of iRadimed by 19.5% during the fourth quarter. CWM LLC now owns 657 shares of the medical equipment provider’s stock valued at $64,000 after acquiring an additional 107 shares in the last quarter. Johnson Investment Counsel Inc. increased its holdings in shares of iRadimed by 0.7% during the third quarter. Johnson Investment Counsel Inc. now owns 25,842 shares of the medical equipment provider’s stock valued at $1,839,000 after acquiring an additional 187 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of iRadimed by 5.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock valued at $252,000 after acquiring an additional 234 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of iRadimed by 4.8% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,824 shares of the medical equipment provider’s stock valued at $567,000 after acquiring an additional 267 shares in the last quarter. Finally, Quantinno Capital Management LP boosted its position in shares of iRadimed by 12.5% during the first quarter. Quantinno Capital Management LP now owns 3,482 shares of the medical equipment provider’s stock valued at $335,000 after buying an additional 387 shares during the last quarter. Institutional investors own 92.34% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on IRMD shares. Roth Mkm restated a “buy” rating and set a $120.00 target price on shares of iRadimed in a report on Tuesday, February 10th. Lake Street Capital restated a “buy” rating and set a $120.00 target price on shares of iRadimed in a report on Wednesday, February 11th. Weiss Ratings downgraded iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, May 20th. Finally, Freedom Capital upgraded iRadimed to a “strong-buy” rating in a report on Thursday, April 2nd. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $120.00.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.